The Inhibition of Histone Lysine Demethylases Affects Head and Neck Cancer Cell Growth and Response to Cisplatin
Genes · 30.08.2026 · 17 (9) · 1047
DOI: 10.3390/genes17091047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 30.08.2026. Verfasst von Dawid Dorna und 3 weiteren Autor:innen. Beteiligte Einrichtung: Poznan University of Medical Sciences, Doctoral School, 60-812 Poznań, Poland. Hauptthemen laut MEDLINE: Cisplatin, Head and Neck Neoplasms, Histone Demethylases, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre.
Abstract (Originalsprache)
Background/Objectives: Head and neck squamous cell carcinomas (HNSCC) are a heterogenous group of tumors, which are usually treated with surgery and radiotherapy, while chemotherapy (e.g., cisplatin), anti-EGFR, or immune checkpoint inhibitors are used to treat locoregionally advanced and recurrent cases. However, survival outcomes are still unsatisfactory, and novel augmenting treatments are required. Recently, histone lysine demethylases (KDMs) emerged as promising anti-cancer targets. In order to further characterize KDM4–6 as pharmacological targets in HNSCC, we evaluated changes in KDM4/5/6 expression in HNSCC patients, and we experimentally assessed the biological effects of inhibitors of KDM4/5/6 in HNSCC cell lines.
Methods
We used online tools (TIMER, GEPIA3, UALCAN) to analyze TCGA data from HNSCC patients. Then, we used resazurin assay to assess the effect of ML324, GSK-J4, and JIB-04 (the inhibitors of KDM4, KDM6, and KDM4–6, respectively) on cell viability in two-dimensional (2D) and three-dimensional (3D) culture of FaDu, SCC-152, and Detroit-562 cells. The potential for cisplatin sensitization was also assessed. Gene/protein expression was evaluated by qPCR and antibody array.
Results
We found that the majority of the analyzed KDMs were overexpressed in HNSCC, except KDM4C, KDM5D, and KDM6A. All three studied inhibitors significantly reduced cell viability in 2D and 3D cell cultures. Moreover, the pre-treatment of cells with KDM inhibitors showed moderate potential for cisplatin sensitization. In addition, the chemicals significantly reduced the expression of pluripotency markers, especially SOX2.
Conclusions
In conclusion, KDM4–6 inhibitors significantly affected HNSCC cell growth, and exerted the potential for epigenetic priming in combination with cisplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Poznan University of Medical Sciences, Doctoral School, 60-812 Poznań, Poland.
- Poznan University of Medical Sciences, Department of Pharmaceutical Biochemistry, 60-806 Poznań, Poland.
ORCID-Profile: Dawid Dorna, Robert Kleszcz, Violetta Krajka-Kuźniak, Jarosław Paluszczak
Förderung
- National Science Centre
Zitieren
APA
Dorna, D., Kleszcz, R., Krajka-Kuźniak, V., & Paluszczak, J. (2026). The Inhibition of Histone Lysine Demethylases Affects Head and Neck Cancer Cell Growth and Response to Cisplatin. Genes, 17(9), 1047. https://doi.org/10.3390/genes17091047
Vancouver
Dorna D, Kleszcz R, Krajka-Kuźniak V, Paluszczak J. The Inhibition of Histone Lysine Demethylases Affects Head and Neck Cancer Cell Growth and Response to Cisplatin. Genes. 2026;17(9):1047. doi:10.3390/genes17091047
BibTeX
@article{Dorna2026,
author = {Dorna, Dawid and Kleszcz, Robert and Krajka-Kuźniak, Violetta and Paluszczak, Jarosław},
title = {The Inhibition of Histone Lysine Demethylases Affects Head and Neck Cancer Cell Growth and Response to Cisplatin},
journal = {Genes},
year = {2026},
volume = {17},
number = {9},
pages = {1047},
doi = {10.3390/genes17091047}
}
EUVIMED